15th October 2024, Tuesday

TechPharus

Latest Posts

HealthTech News

  • French psychiatrists of the 19th century may be unsung heroes of modern melancholia research
    on October 15, 2024 at 6:41 pm

    In an era where mental health awareness is at the forefront of public discourse, a new historical review is shedding light on the often-overlooked French contributions to our understanding of depression. Published in Genomic Psychiatry, the study by Dr. Kenneth S. Kendler and Virginia Justis of Virginia Commonwealth University examines a seminal 1897 French monograph that helped shape modern concepts of melancholia and depression.

  • Immune signatures may predict adverse events from immunotherapy
    on October 15, 2024 at 6:39 pm

    Distinct immune “signatures” in patients who develop adverse events while receiving immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side effects, suggests a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

  • Despite national efforts, cancer clinical trials are becoming less diverse, study finds
    on October 15, 2024 at 6:36 pm

    In the U.S., millions of people experience cancer every year, but don’t have an equal opportunity to access experimental treatments in clinical trials, or to receive treatments that have been shown to be effective in patients like them.

  • FDA approves Hympavzi for hemophilia
    on October 15, 2024 at 5:30 pm

    The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

  • FDA says compounding pharmacies can keep making weight-loss med tirzepatide, for now
    on October 15, 2024 at 5:20 pm

    Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.